<DOC>
	<DOC>NCT02390219</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of LUM/IVA combination therapy in subjects 12 years and older with CF and advanced lung disease and who are homozygous for the F508del CFTR mutation</brief_summary>
	<brief_title>Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Homozygous for the F508delCFTR mutation; historical genotype must be documented in the participant's source documents. Percent predicted FEV1 &lt;40 of adjusted for age, sex, and height at Screening Participant currently receiving invasive mechanical ventilation. History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant Any clinically significant laboratory abnormalities at screening that would interfere with the study assessments or pose an undue risk for the subject A 12lead electrocardiograms (ECG) demonstrating QTcF &gt;450 msec at Screening History of solid organ or hematological transplantation History of alcohol or drug abuse in the past year Ongoing or prior participation in an investigational drug study (including studies investigating lumacaftor and/or ivacaftor) within 30 days of screening. Use of strong inhibitors, moderate inducers, or strong inducers of CYP3A Pregnant and nursing females: Females of childbearing potential must have a negative pregnancy test at Screening and Day 1. Sexually active subjects of reproductive potential who are not willing to follow the contraception requirements Use of beta blockers or the equivalent at Screening.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>